openPR Logo
Press release

Biosimilars And Follow-On Biologics Market Growth, Trends, Absolute Opportunity and Value Chain 2016-2026

02-15-2017 12:54 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

Biosimilars And Follow-On Biologics Market Growth, Trends,

Biosimilars is defined as a type of biological product that is similar to another drug, which has already been licensed (approved) by the US FDA or European Medicines Agency. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. These drugs are also coined as follow-on biologics and are mostly derived from biological sources such as bacterium and yeast. The constitution of the biosimilar drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biosimilars are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biosimilars can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. A good example for this is Pfizer acquisition of Hospira, to gain access to the latter’s attractive biosimilars portfolio. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biosimilar drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.

Biosimilars and Follow-on Biologics Market: Drivers and Restraints

Drivers for the biosimilars market include big brand name drugs losing patent extensions, cuts in healthcare costs across nations, forming of incentivized pricing policies by companies in order to access high growth pharmerging markets and good development in pharmacovigilance procedures across the globe. Other factors increasing the demand for biosimilar drugs include rising disease incidences across the globe and better access to healthcare for all nations.

Restraints for the market include constraints in developing and registering biosimilar drugs and the complexity in the manufacturing processes. The drugs are difficult to verify and have to undergo complex regulations. Further, the drugs are different from each other due to variability in raw material and in the manufacturing process, which is expected to deter the future development of biosimilar drugs. There are also risks in having an increase in the versions of an identical biosimilar drug.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1250

Biosimilars and Follow-on Biologics Market: Segmentation

Biosimilars and Follow-on Biologics Market can be segmented into these following ways:

Segmentation by product class

epoetins;

filgrastims;

insulins;

growth hormones;

alfa interferons;

monoclonal antibodies;

beta interferons;

follitropins;

low-molecular-weight heparins (LMWH).

Segmentation by application

Rheumatoid arthritis

Anemia

Cancer

Diabetes

Others

Segmentation by regions

Biosimilars and Follow-on Biologics Market: Overview

Biosimilar market is expected to gain prominence over the forthcoming years due to leading biologic drugs expected to lose exclusivity over the next seven years. Further, biosimilar drugs, once formed, are expected to generate cost savings for the patient population. Competition is expected to be limited in the market as the drugs are expected to be formed using various types of innovative technologies. Biosimilars may generate smaller savings for drug makers because of their complexity as well as regulatory challenges of getting FDA approvals.

Biosimilars and Follow-on Biologics Market: Region-wise Outlook

Depending on geographic regions, biosimilar drug market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.

In terms of geography, Europe dominates the market, followed by Asia-Pacific. However, rising technological advancement in healthcare and systematic drug review process will drive the markets over North America, Japan and other regions. Europe dominates the biosimilars market driven by technically advanced healthcare infrastructure and high patient awareness & regulatory harmonization. Increasing funding for development of biosimilar drugs, availability of high-quality research infrastructure and strategies developed by drug makers to restrict entry of new players. Emerging markets include Eastern European countries followed by countries in Eastern Africa. Rising disease incidences in these countries is expected to prove favorable for the growth of the biosimilar drug market.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1250

Biosimilars and Follow-on Biologics Market: Key Players

Some of the key players in biosimilar market are Pfizer Inc. (AC. Hospira), Sandoz International GmbH, , Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Biocon Limited, Mylan, Inc. , Amgen, Celltrion Inc., Roche Diagnostics, and Merck KGaA.

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars And Follow-On Biologics Market Growth, Trends, Absolute Opportunity and Value Chain 2016-2026 here

News-ID: 437835 • Views: 205

More Releases from Future Market Insights

How Changing Dynamics of Cable Testing Market are Reflecting on Growth Strategie …
Global Cable Testing Market: Introduction The cost of the substitution of cables that are concealed is very high. Faults in the cable, bending, kinking, and crushing, are not always visible, which has created the requirement for cable testing. Thus, cable testing helps check the cable functionality, cable quality, and cable conformity. Several times, cable testing by visual inspection is an effective way of identifying the actual problem before it causes any
How Transformative Trends in Self-Organising Network Market are Molding Strategi …
Self-Organising Network: Introduction With accelerated advancements and increasing complexities in the radio network technologies, such as those utilised for the development of LTE and 5G networks, which are used for planning, management, configuration, healing and optimisation, are required to be automated to facilitate efficiency. At present, suppliers are offering self-organising networks that possess the ability to offer optimum performance. Self-organising networks are use cases that perform network governance, including network planning,
Mining Vehicle AC Kits Market: Exploring the Impact of Trends on Strategies of K …
Mining Vehicle AC Kits Market: Introduction Cabin space in mining equipment has become more sophisticated in the recent past. The installation of mining vehicle AC kits has evolved from an optional feature to a necessary feature. Mining equipment manufacturers have made advancements in technology related to efficiency, performance and cost of air conditioning systems in order to make them affordable and economical to enable low-budget and compact installations without compromising on
Key Factors to Fuel Growth of the Talent Acquisition & Staffing Technology and S …
With the growing importance of recruiting and retaining top talent effectively and efficiently, smart hiring processes are the need of the hour. It is about time organisations move beyond merely scrutinising resumes. Salaries and benefits are important factors, but adopting ways that would make candidates an important part of the hiring process will attract the best talent. Studies reveal that due to discrepancies in existing Applicant Tracking Systems (ATS), hiring

All 5 Releases


More Releases for Biosimilar

Global Biosimilar Drug Sales Market Report 2018
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Free | Request Sample Copy of the Report @ https://bit.ly/2M8e47Z Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Biosimilar Drug for
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014. Trastuzumab or
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.